Ondansetron 4MG and 8MG
ID: SPE2D223R0007Type: Presolicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/78991b7acb26473fb3df647f2a7cc6a8/view
Timeline
    Description

    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Ondansetron. This contract will establish a national supply source to provide Ondansetron HCL 4 and 8MG Tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. The projected solicitation date is March of 2023.

    Lifecycle
    Title
    Type
    Ondansetron 4MG and 8MG
    Currently viewing
    Presolicitation
    Similar Opportunities
    Rizatriptan Benzoate
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rizatriptan Benzoate tablets. The contract will establish a national supply source to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The solicitation will be posted on the DLA Bid Board System and SAM.gov. Interested parties should contact Keith Ryales for any questions/comments. The projected solicitation date is June 2022.
    Valsartan
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Valsartan, a drug used for treating high blood pressure and heart failure. The contract will include Valsartan tablets in various strengths and quantities. It will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties can contact Catherine Gilbert for more information. The solicitation is projected to be issued in December 2019.
    Famotidine
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Famotidine, a drug used to treat ulcers and gastroesophageal reflux disease (GERD). The contract will include Famotidine 20 MG tablets in various bottle sizes and Famotidine 40 MG tablets in different bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. The contract aims to establish a national supply source to provide the items for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The annual usage estimates will be provided in the solicitation. The solicitation is expected to be posted on the DLA Bid Board System (DIBBS) and SAM.gov. For any questions or comments, interested parties should contact Kristen Baraniewicz. The projected solicitation date is August 2022, but DLA reserves the right to issue the solicitation before or after that date.
    Valsartan
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Valsartan, a drug used to treat high blood pressure and heart failure. The contract will include Valsartan tablets in various strengths and quantities. It will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The solicitation will be posted on the DLA Bid Board System and beta.SAM.gov, with a projected solicitation date in June 2021. Interested parties should contact Christopher Newman for more information.
    Pantoprazole DR Tablets
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE Pantoprazole DR Tablets: The Defense Logistics Agency is planning to issue a national requirements contract for Pantoprazole DR Tablets. These tablets, available in 20MG and 40MG strengths, will be provided in 90 and 1000 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The tablets will be purchased by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the solicitation. Interested parties can find more information on the DLA Bid Board System and Beta Sam.Gov websites. The solicitation is projected to be issued in September 2021.
    6505--Zolmitriptan Tablets (VA-25-00006129)
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting bids for the procurement of Zolmitriptan tablets, as outlined in solicitation number VA-25-00006129. This contract aims to establish a reliable source of pharmaceutical supplies for federal healthcare programs, emphasizing compliance with the Drug Supply Chain Security Act (DSCSA) and good manufacturing practices as mandated by the FDA. The selected contractor will be responsible for providing competitive pricing for both the base year and four option years, ensuring that all products meet safety and regulatory standards. Interested parties should contact Contract Specialist Kenneth Lay at Kenneth.Lay@va.gov for further details and to discuss submission requirements.
    Doxycycline Hyclate
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Doxycycline Hyclate. The contract will establish a national supply source to provide Doxycycline Hyclate 100MG Tablets in various bottle sizes. This acquisition is for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be firm-fixed price, requirements type with a one year base and four one year options. Interested parties should contact Catherine Gilbert for more information. The projected solicitation date is September 2019.
    Ibuprofen 400MG/600MG/800MG Tablets
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Ibuprofen 400MG/600MG/800MG Tablets. The contract will establish a national supply source to provide the items for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is March of 2023.
    Rabeprazole Sodium Delayed Release Tablets
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.
    Telmisartan Tablets
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Telmisartan Tablets. Telmisartan Tablets are pharmaceutical preparations used to treat high blood pressure and reduce the risk of heart attack, stroke, and kidney problems in certain patients. The tablets will be available in 20MG, 40MG, and 80MG strengths, packaged in 30 count bottles. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. The contract aims to establish a national supply source to provide Telmisartan Tablets to Department of Defense, Bureau of Prisons, Indian Health Service, and Department of Veterans Affairs customers through the DLA and VA prime vendor programs. Interested parties can contact Courtney Hunter-Stangler at (215) 737-6845 or Courtney.Hunter-Stangler@dla.mil for any questions/comments. The solicitation is projected to be issued in August of 2024.